Spruce Biosciences (SPRBD) Stock Price, News & Analysis

Company Overview

Spruce Biosciences, Inc. is a clinical-stage specialty biopharmaceutical company focused on developing targeted therapies for rare endocrine diseases. The company’s research strategy centers on modulating the hormonal axis to address underlying disease mechanisms rather than treating symptoms alone. By concentrating on orphan indications with high unmet medical need, Spruce aims to deliver novel treatment options for patients who have limited alternatives under current standard-of-care regimens.

Spruce’s lead product candidate is tildacerfont, an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist in development for adults with classic congenital adrenal hyperplasia (CAH). The company is also advancing relacorilant, a selective glucocorticoid receptor modulator licensed from Corcept Therapeutics, for use in endogenous Cushing’s syndrome. Both programs have progressed through Phase 2 clinical trials, demonstrating favorable safety profiles and biomarker responses that support further study in pivotal trials.

Founded in 2019 and headquartered in Redwood City, California, Spruce Biosciences operates a compact research and development infrastructure in the San Francisco Bay Area. The company is led by President and Chief Executive Officer Megan O’Connor, whose leadership team combines expertise in endocrinology, drug development and commercialization. With its pipeline poised for late-stage development, Spruce is preparing for potential regulatory filings and global partnerships to extend its therapies to patient populations worldwide.

Key Stats

• Today's Range: $8.32 to $12.75
• 50-Day Range: N/A
• 52-Week Range: $4.28 to $45.60
• Volume: 75,838 shs
• Average Volume: 9,786 shs
• Market Capitalization: $6.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Spruce Biosciences Stock Analysis - MarketRank™

Spruce Biosciences scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Spruce Biosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Spruce Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spruce Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of Spruce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Spruce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spruce Biosciences has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spruce Biosciences does not currently pay a dividend.

Dividend Growth

Spruce Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of Spruce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Spruce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spruce Biosciences has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

Spruce Biosciences has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Spruce Biosciences this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spruce Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Spruce Biosciences is held by insiders.

Percentage Held by Institutions

91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SPRBD Stock Analysis - Frequently Asked Questions

How have SPRBD shares performed this year?

Spruce Biosciences' stock was trading at $9.01 on January 1st, 2025. Since then, SPRBD stock has increased by 37.6% and is now trading at $12.40.

How do I buy shares of Spruce Biosciences?

Shares of SPRBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTC
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTC:SPRBD
• Previous Symbol: OTC:SPRBD
• CIK: 1683553
• Web: www.sprucebiosciences.com
• Phone: (650) 600-2400
• Fax: N/A
• Employees: N/A
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 562,000
• Free Float: N/A
• Market Cap: $6.97 million
• Optionable: N/A
• Beta: 2.43